Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

TRI-STATE HEALTH, INC.

NPI: 1609348325 · ELKTON, MD 21921 · Clinical Medical Laboratory · NPI assigned 12/19/2018

$2.08M
Total Medicaid Paid
31,776
Total Claims
21,529
Beneficiaries
4
Codes Billed
2020-03
First Month
2024-12
Last Month

Provider Details

Authorized OfficialNIAZ, MUHAMMED (MD)
Parent OrganizationTR-STATE HEALTH INC
NPI Enumeration Date12/19/2018

Related Entities

Other providers sharing the same authorized official: NIAZ, MUHAMMED

ProviderCityStateTotal Paid
TRI-STATE HEALTH, INC. ELKTON MD $3.60M
TRI-STATE HEALTH, INC ELKTON MD $384K
TRI-STATE HEALTH, INC ELKTON MD $52K
TRI-STATE HEALTH, INC NORTH EAST MD $42K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2020 3,651 $269K
2021 7,763 $526K
2022 7,635 $478K
2023 7,398 $467K
2024 5,329 $344K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 7,242 6,049 $893K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 12,512 7,373 $608K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 5,691 4,238 $518K
80305 6,331 3,869 $64K